AcronGenomics And Molecular Vision Ltd. Take Further Steps Towards The First Milestone For Diabetes Monitoring

GENEVA--(BUSINESS WIRE)--Acrongenomics, Inc. (OTCBB:AGNM) and Molecular Vision, Ltd. -- an Imperial Innovations spin-out company -- today present a second R&D update of their joint collaboration, following the meeting that took place on 27th September 2006 at Acrongenomics’ headquarters in Geneva. The ultimate goal of the partnership is to develop and commercialize smart Point-of-Care (POC) diagnostic devices based on the innovative technology platform offered by Molecular Vision’s experts.

Back to news